Information  X 
Enter a valid email address

ValiRx in collaboration agreement with DKFZ

By BFN News | 07:51 AM | Thursday 13 November, 2014


ValiRx, the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, has entered into a collaboration agreement with the DKFZ for the further development of ValiRx's proprietary Gene Inactivation through Chromatin Engineering technology platform (known as GeneICE). The goal of the research is to develop new targeting technologies that will improve the early detection and diagnosis of various cancers and new GeneICE compounds aimed at enhancing treatment outcomes. This Agreement builds on the ValiRx-DKFZ association with in the Eurostars programme, named 'D-SIST' and announced on 15 August 2013 by expanding the scope of the research to cover a wider range of activities relating to the development of the GeneICE technology and its use in the treatment of cancer, as well as its diagnostic and research applications. Story provided by StockMarketWire.com

a d v e r t i s e m e n t